Publication

/Publication

Meta analysis of two phase 1b randomized, double blind, placebo controlled clinical trials of the HBV therapeutic vaccines TG1050 and T101 developed in Europe/Canada or China

Poster 0710-AASLD 2019-TG1050-T101_Metaanalyse Fabien Zoulim et al. AASLD 2019 Download [...]

By |2020-03-22T17:47:45+01:00novembre 8th, 2019|Publication, TG1050|Commentaires fermés sur Meta analysis of two phase 1b randomized, double blind, placebo controlled clinical trials of the HBV therapeutic vaccines TG1050 and T101 developed in Europe/Canada or China
Read More

The efficacy and safety of Tipapkinogen Sovacivec (TG4001) therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up

Diane. M. Harper, et al. Gynecologic Oncology, April 2019 - [...]

By |2019-07-01T11:48:29+02:00avril 18th, 2019|Publication, TG4001|Commentaires fermés sur The efficacy and safety of Tipapkinogen Sovacivec (TG4001) therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up
Read More

Investigational treatment combining TG1050, an HBV-specific immunotherapeutic, with direct acting antivirals or immunomodulators, improves sustained antiviral effects and immune responses in HBV-persistent mice

Roland Kratzer, et al. AASLD, The Liver Meeting 2018, November [...]

By |2019-07-01T15:33:42+02:00novembre 30th, 2018|Publication, TG1050|Commentaires fermés sur Investigational treatment combining TG1050, an HBV-specific immunotherapeutic, with direct acting antivirals or immunomodulators, improves sustained antiviral effects and immune responses in HBV-persistent mice
Read More

Safety and Immunogenicity of Single and Multiple Injections of the Therapeutic Vaccine TG1050 in NUC-Suppressed Chronic Hepatitis B (CHB) Patients: Unblinded Analysis of a Double-Blind, Placebo-Controlled Phase 1b Study

Claire Fournier, et al. AASLD, The Liver Meeting 2018, November [...]

By |2019-07-01T14:15:26+02:00novembre 7th, 2018|Publication, TG1050|Commentaires fermés sur Safety and Immunogenicity of Single and Multiple Injections of the Therapeutic Vaccine TG1050 in NUC-Suppressed Chronic Hepatitis B (CHB) Patients: Unblinded Analysis of a Double-Blind, Placebo-Controlled Phase 1b Study
Read More
Transgene sa
400 Boulevard Gonthier d’Andernach - Parc d'Innovation - CS80166 67405 Illkirch Graffenstaden Cedex - France | Tel. : + 33 (0) 3 88 27 91 00 - Fax. : + 33 (0) 3 88 27 91 11
© 2019 Transgene - All rights reserved
Mentions légales - Crédits